6ZY.F · Zynerba Pharmaceuticals, Inc

-

Please sign in to comment on 6ZY.F

1 Comment

Admin

3 years, 7 months ago

Zynerba Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 13.1% above its 200 day moving average.

From a valuation standpoint, the stock is 13.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1134.7.

Zynerba Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 10.2% to $-10M since the same quarter in the previous year.

Finally, its free cash flow grew by 6.2% to $-7M since the same quarter in the previous year.

Based on the above factors, Zynerba Pharmaceuticals, Inc gets an overall score of 4/5.

Sector	Healthcare
Industry	Drug Manufacturers-Specialty & Generic
ISIN	US98986X1090
CurrencyCode	EUR
Exchange	F

Beta	1.74
Market Cap	20M
PE Ratio	None
Dividend Yield	0.0%
Target Price	7.63

ABOUT

Zynerba Pharmaceuticals, Inc

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

6ZY.F · Zynerba Pharmaceuticals, Inc

-

Zynerba Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Zynerba Pharmaceuticals, Inc using a moving average strategy